Example: Heart Attack

Search clinical trials for: Integrase Inhibitors

Total 472 results

NCT02691065

Unknown status

Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection

Conditions: HIV
NCT04460924

Recruiting

ARTiBIOME: Observational Study on the Effect of HIV and ART on Gut Microbiome

Conditions: HIV Infections
NCT04019873

Recruiting

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

Conditions: HIV Infections
NCT00298350

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

Conditions: HIV; HIV-1; Human Immunodeficiency Virus
NCT04636437

Not yet recruiting

Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Conditions: HIV Infections
NCT00397566

Withdrawn

A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects

Conditions: HIV Infections
NCT00807443

Completed

Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1

Conditions: HIV-1; HIV Infections
NCT03280940

Completed

Impact of Different Integrase Inhibitor Based Regimen on Immune Activation Among HIV naïve Patient (INTATTI)

Conditions: HIV Infections
NCT01231516

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Conditions: Infection, Human Immunodeficiency Virus; HIV Infections
NCT00488059

Terminated

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

Conditions: HIV Infections
NCT01328041

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Conditions: Infection, Human Immunodeficiency Virus
NCT00935480

Completed

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients

Conditions: HIV Infections
NCT00520897

Completed

Integrase Inhibitor (MK-0518) Viral Decay

Conditions: HIV Infections
NCT01288417

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Conditions: HIV Infections; HCV Infections
NCT02938520

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Conditions: HIV Infections
NCT04820933

Not yet recruiting

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

Conditions: HIV I Infection; Cardiovascular Risk Factor; Lipid Metabolism Disorders
NCT04319718

Recruiting

Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048

Conditions: Pharmacokinetics; Safety
NCT02076178

Completed

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Conditions: Infection, Human Immunodeficiency Virus
NCT01896921

Completed

Switch to Maraviroc + Integrase Inhibitor

Conditions: HIV
NCT02383108

Completed

Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children

Conditions: HIV Infection
NCT01048671

Completed

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

Conditions: HIV Infections
NCT03696160

Recruiting

The Late Presenter Treatment Optimisation Study

Conditions: HIV/AIDS
NCT01302847

Active, not recruiting

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Conditions: HIV Infections
NCT03327740

Completed

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Conditions: Infection, Human Immunodeficiency Virus I
NCT01568892

Completed

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

Conditions: HIV Infections